Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. Founded in 1999, Genmab utilizes its next-gen antibody technologies to create novel therapies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
For more information, please visit Genmab.com